APOB and obesity disorder: The rise in obesity and diabetes globally results in dyslipidaemia characterised by a fall in HDL-C and a rise in non-HDL-C and high triglyceride levels [8, 9], hence health systems should pragmatically move towards using non-HDL-C or apo B as a unifying measure of atherogenic lipid risk.